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The purpose of this study was to investigate the usefulness of quantitative proton magnetic resonance spectroscopy (1H-MRS) for
characterizing breast lesions at 1.5T, and to evaluate the diagnostic performance of in vivo breast 1H-MRS using receiver operating
characteristics (ROC) analysis. 112 patients (99 malignant and 13 benign tumors) who were scanned with the MRI/MRS protocol
wereincludedinthisstudy.Choline-containingcompounds(tCho)levelsweremeasuredandcomparedwithhistologicalﬁndings.
The measured tCho levels in this work had range of 0.08–9.99mmol/kg from 65 (66%) of 99 patients with malignant tumors. Of
the 13 benign lesions, 1H-MRS detected one as false positive, with tCho level of 0.66mmol/kg. The optimal tCho level cutoﬀ
point that yielded the highest accuracy was found to be >0.0mmol/kg. The resulting sensitivity was 66% and speciﬁcity 92% for
distinguishing benign from malignant lesions. The tCho levels were found to be higher in invasive cancer compared to ductal
carcinoma in situ or benign lesions, possibly associated with more aggressive behavior or faster cell replication in invasive cancer.
Quantitative in vivo 1H-MRS may provide useful information for characterizing histopatholoigical types in breast cancer.
1.Introduction
High-resolution anatomic magnetic resonance imaging
(MRI) and dynamic contrast-enhanced MRI have evolved
into a standard clinical tool for detection and diagnosis of
breast lesions [1, 2]. The morphological appearance and
enhancement kinetics are two essential elements [3, 4].
However, despite its high sensitivity (94%–100%), MRI also
detectsmanyincidentalenhancedlesions.Thelowspeciﬁcity
(37%–97%) may cause great anxiety to patients and many
unnecessary biopsies or overtreatment [5–7]. Other adjunct
imaging modalities that can better characterize the enhanc-
ing lesions on MRI are greatly needed.
In vivo proton MR spectroscopy (1H-MRS) is a nonin-
vasive technique that has great potential to provide tumor
metabolism,whichmaybeusedintumordiagnosisandeval-
uating the therapeutic response of the tumor [8–11]. Re-
cently, breast 1H-MRS has been shown to improve cancer
diagnosis based on elevated choline-containing compounds
(tCho) metabolite peak. Several studies conducted at 1.5T
have shown that in vivo 1H-MRS can be used to distin-
guish between benign and malignant tissues based on the
hypothesis that tCho is only detectable in malignancies [8–
10, 12, 13]. A pooled analysis of these studies showed that
this tCho detectability criterion could identify malignancies
with 89% sensitivity and 87% speciﬁcity. A similar study
has been performed at higher ﬁeld (e.g., 4T) showing that
the increased sensitivity allows detection of tCho in benign
lesions and normal subjects [14]. Levels of tCho were found
to be elevated in malignancies compared to benign lesions.
The sensitivity and speciﬁcity of the measurements were
found to be 46% and 94%, respectively. Therefore, a more
general approach is to quantify the tCho peak with the
assumption that tCho levels are higher in malignancies than
in benign lesions or normal tissues [14–17].
In this study, we applied an internal method using water
as a reference to quantify absolute tCho levels in 112 patients
with breast tumors. The purpose of this study was to inves-
tigate the usefulness of quantitative single-voxel 1H-MRS for
characterizing breast lesions at a clinical 1.5T scanner and to2 The Scientiﬁc World Journal
evaluate the diagnostic performance of breast 1H-MRS using
ROC (receiver operating characteristics) analysis. The per-
formance in diﬀerent tumor-size groups and between inva-
sive cancer, in situ cancer, and benign lesions were evaluated.
2. Patientsand Methods
2.1. Patients. 112 patients (range 31–78 years old, mean 51
years) who were scanned with the MRI/MRS protocol were
included in this study. All patients had suspicious ﬁndings
on physical examination, mammography, or sonography in
the breast. They were referred to the study by medical or
surgicaloncologists. Theinclusion criteria werepatients who
had suspicious lesions scheduled for biopsy or who already
had diagnosis of malignant breast lesions with needle biopsy.
Therefore,thisisaselectivepatientgroup,notinadiagnostic
setting. Only lesions greater than 1cm were scanned with the
MRS protocol and included in this study. Exclusion criteria
were lesions smaller than 1cm, or with presence of a breast
hematoma adjacent to the suspicious lesion. This study was
approved by the institutional review board and was HIPPA
compliant. The informed consent was obtained from each
patient prior to the study.
The tissue diagnosis was obtained from the pathological
report of the excision or needle biopsy. Of the 112 breast
lesions evaluated, 99 (88%) were malignant and 13 (12%)
were benign. Of the 99 malignant lesions, 66 were invasive
ductal carcinoma (IDC), 10 were invasive lobular carcinoma
(ILC), 12 were invasive ductal and lobular carcinoma
(Mixed), and the other 11 were in situ ducal carcinoma
(DCIS). Of the 13 benign lesions, 7 were ﬁbroadenomas, 5
were ﬁbrocystic changes, and 1 was atypical hyperplasia.
2.2. MR Imaging. All patients were examined with the same
MRI/MRS protocol, which consisted of high-resolution im-
aging, dynamic contrast-enhanced MR imaging, and MR
spectroscopy. The studies were performed on a clinical 1.5T
whole-body system (Eclipse; Philips Medical System, Cleve-
land, Ohio) with the standard MRS acquisition software
provided by the manufacturer. A body coil was used for
transmission, and a dedicated four-channel phased-array
breast coil (USA Instruments, Aurora, Ohio, USA) was used
for both MR imaging and MR spectroscopy. The coil was the
original coil that came with the scanner, designed to permit
simultaneous imaging of both breasts. It did not allow for
selective conﬁguration of channels depending on the volume
of interest.
All patients were examined in prone position, and the
breasts were gently cushioned with rubber foam to reduce
patient motion. After the localizer scan, sagittal view T1-
weighted precontrast images were acquired from the breast
of concern, using a spin-echo (SE) sequence with TR/TE
1000/12ms, matrix size 256 × 256, ﬁeld of view (FOV)
22cm, and 34 slices with 3-4mm thickness. Following this, a
3D SPGR (RF-FAST) pulse sequence with 16 frames (repeti-
tions) was prescribed for bilateral dynamic imaging. Thirty-
two axial slices with 4mm thickness were used to cover both
breasts. The imaging parameters were TR/TE 10ms/3.6ms,
ﬂip angle 20◦, acquisition matrix size 256 × 128, and FOV
varying between 32 and 38cm. The scan time was 42 seconds
per acquisition. The sequence was repeated 16 times for
dynamicacquisitions,4precontrast,and12postcontrastsets.
The contrast agent (Omniscan, 1cc/10 lbs body weight) was
manually injected at the beginning of the 5th acquisition
and was timed to ﬁnish in 12 seconds to make the bolus
length consistent for all patients. Immediately following the
contrast, 10cc saline was used to ﬂush the contrast medium.
The subtraction images were generated on the scanner cons-
ole, by subtracting the pre-contrast images acquired in frame
no. 3 from the 1min postcontrast-enhanced images acquired
in frame no. 6.
2.3. MR Spectroscopy. The subtraction images were used for
placing the volume of interest for the subsequent MRS. The
spectroscopic voxel was carefully positioned to maximize
coverageoftheenhancedlesiononthesubtractionimages,as
well as the hypointense lesion if it was visible on the sagittal
precontrast T1-weighted images. Localized single-voxel 1H-
MR spectra were acquired from the enhanced lesion. The
voxel size was 4.8–8.0mL. Localization was obtained using
the point-resolved spin-echo sequence (PRESS) [18, 19]f o l -
lowed by voxel shimming. The typical water peak linewidth
(FWHM) ranged from 8 to 17Hz. The spectra were acquired
with water suppression and fat attenuation via three CHESS
pulses [20, 21] with 60Hz bandwidth and frequency-
selective presaturation pulse (FATSAT), respectively. The fol-
lowing acquisition parameters were used: TR = 2000ms,
TE = 270ms, 128 acquisitions, spectral width = 1953Hz, and
2048 data points. A fully relaxed, unsuppressed spectrum
(TR/TE = 2000/270ms, 24 acquisitions) was also acquired to
measure the amplitude of the water peak in the localized vol-
ume as the internal reference. After including the additional
time for voxel placement and shimming, the total scan time
for the entire sequence can be completed within 15 minutes.
2.4. MR Imaging Data Analysis. Measurement of tumor
size was done based on the maximum intensity projection
(MIP) of subtraction images. The longest dimension and the
longest perpendicular dimension of the MIP were measured.
The equivalent 1-dimensional tumor size was calculated
by taking square root of their product. The malignant le-
sions were divided into three size groups as 1.0–1.9cm
(Group A), 2.0–2.9cm (Group B), and 3.0cm or above
(Group C). The processing of subtraction, MIP, and size
measurements were carried out using the “ImageJ” software
(http://rsb.info.nih.gov/ij/).
2.5. MR Spectroscopy Data Analysis. The jMRUI software
package [22] was used for time-domain analysis. For the un-
suppressed spectra used to measure the water peak, each
free induction decay signal was ﬁrst zero-ﬁlled to 4096
points. After Fourier’s transformation, automatic (or man-
ual) phasing was used to correct every signal with the zero
order phase of its water peak. The maximum peak of the
water signal was assigned to 4.7ppm, implicitly setting the
polymethylenelipidpeakat1.32ppm.Forpreprocessingand
quantiﬁcation of the water signal, we selected a frequency
range of 4.2–5.2ppm. In order to measure tCho peak fromThe Scientiﬁc World Journal 3
the suppressed spectrum, we performed a preprocessing that
consistedofzero-ﬁllingof4096points,Gaussianapodization
of5Hz,Fourierstransformation,andphasecorrectionofthe
transformedspectrum.Anarrowfrequencyrange(e.g.,2.92–
3.52ppm) was selected for analyzing tCho peak to quantify
its amplitude.
The spectrum was ﬁrst inspected, and the signal-to-noise
ratio (SNR) of the tCho peak with respect to the noise level
was measured. When SNR > 2, the peak was ﬁtted and the
concentration calculated. AMARES (advanced method for
accurate, robust and eﬃcient spectral ﬁtting) [23], a widely
used quantitation tool for MRS data, was employed to ﬁt the
spectra. In this study, a Gaussian lineshape model was cho-
sen for quantifying the tCho peak. Soft constraints were im-
posed for a faster and more accurate quantitation during
spectral ﬁtting. Linewidths for the tCho peak were allowed
to vary between 1 and 10Hz. The frequency constraint
rangewasrestrictedto ±0.2ppm(e.g.,3.12–3.32ppm).After
the zero- and ﬁrst-order phases were switched oﬀ, the fre-
quency-selective option [24] was applied, weighting the ﬁrst
20 points of the time domain signal by the ﬁrst quarter
of a squared sine function. The Cramer-Rao lower bound
(CRLB) was used as a measure of ﬁtting accuracy [25].
Uncertainty in the estimated tCho concentration was the
standard deviation (SD) of the tCho signal amplitude as
estimated using the CRLB. In the water unsuppressed spec-
tra, water peak was ﬁt at 4.7ppm.
Absolute quantiﬁcation of tCho concentration was ac-
quired using the water peak as an internal reference. All ac-
quisitions were recorded at maximum receiver gain which
made corrections for diﬀerent receiver setting unnecessary.
Hence, the absolute tCho concentration was calculated based
on the following equation:
[tCho] =
nH2O
ntChoMWH2O
×

StCho
SH2O
×

NSH2O 
NStCho

×

fT1H2O
fT1tCho
×
fT2H2O
fT2tCho

,
(1)
where [tCho] is the concentration of the tCho metabolite in
units of mmol/kg, StCho is the signal amplitude of the tCho,
andSH2O isthesignalamplitudeoftheunsuppressedwaterin
the localized spectrum. The terms ntCho and nH2O represent
the number of 1H nuclei in each respective molecule. The
ratio of StCho and SH2O amplitudes can be changed to
molal concentration by correcting for the number of 1H
nuclei per molecule and the molecular weight of water;
MWH2O.

NSH2O and

NStCho are the numbers of data
acquisitions for water unsuppressed and suppressed spectra.
The parameters fT1 and fT2 are the correction factors for
T1 and T2 relaxation times: fT1 = 1 − exp(−TR/T1)a n d
fT2 = exp(−TE/T2). T1 relaxation times were 1513ms for
tCho and 746ms for water; T2 relaxation times were 269ms
for tCho and 97ms for water [16].
2.6. Statistical Analysis. Statistical analysis was performed
using the Microcal software package (Microcal Origin Ver-
sion 6.0 for Windows; Microcal Software Inc., Mass, USA).
The histopathological diagnosis was used as the standard
for evaluating diagnostic performance of 1H-MRS. An ROC
curve was generated from the tCho concentration levels
measured from all tumor lesions. The cut-oﬀ point of the
tCho level was determined as the value that yielded the
highest accuracy, balancing between sensitivity and speciﬁc-
ity. An independent two-tailed, unequal variance t-test was
employed to determine whether tCho detection rate and
concentrationlevel werediﬀerent between invasive cancer, in
situ cancer, and benign lesion groups. A P value <0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Lesion Characteristics. Based on the morphological
pattern of MRI enhancement, all lesions were categorized
into one of two groups according to the American College of
Radiology Breast Imaging Reporting and Data System lexi-
con (ACR BI-RADS): mass-type lesion and non-mass-type
enhancements. In 99 patients with biopsy-conﬁrmed breast
cancer, cancerous lesions showed contrast enhancement in
the DCE-MR imaging. Of the 99 patients with carcinoma,
78 (79%) presented a solitary mass or multiple diﬀerentiable
masses with well-deﬁned borders, and the other 21 (21%)
showed nonmass enhancements without clearly deﬁned bor-
ders. The mean tumor size of these solitary contrast-en-
hanced mass lesions measured on contrast-enhanced MR
imaging was 2.5cm (range 1.0–8.6cm), whereas the size
was 4.8cm (range, 1.6–8.1cm) for the nonmass lesions. The
non-mass-type group had a signiﬁcantly higher tumor size
than the mass-type group (P<0.0002, in Table 1). Of the
13 patients with benign lesions, 8 had mass lesions, with the
mean tumor size of 1.6cm (range, 1.1–2.3cm), and 5 had
nonmass lesions without clearly deﬁned borders.
3.2. MR Spectroscopy Results. The diagnostic performance
of tCho concentration level measured by 1H-MRS was eval-
uated using the ROC analysis (Figure 1). The optimal tCho
level cut-oﬀ point that yielded the highest accuracy was
found to be >0.0mmol/kg. The resulting sensitivity was
66%, speciﬁcity 92%, and overall accuracy 69% for dis-
tinguishing benign from malignant lesions. When a cutoﬀ
of 0.66mmol/kg was selected, the sensitivity was 58%,
speciﬁcity 100%, and overall accuracy 63%. The measured
tCho concentration levels in this work had range of 0.08–
9.99mmol/kg from 65 (66%) of 99 patients with malignant
tumors. This result was consistent with previously published
value (e.g., 0.40–10.0mmol/kg at higher ﬁeld 4T) by Bolan
et al. [14]. In 13 patients with benign lesions, 12 were true-
negative cases (e.g., [tCho] = 0.0mmol/kg) and the remain-
ing one patient with ﬁbrocystic changes was false-positive
case, with tCho level of 0.66 ± 0.10mmol/kg (Table 2).
Figure 2 shows representative MRI and 1H-MRS on
a patient diagnosed by histology with breast cancer (e.g.,
mixedinvasiveductalandlobularcarcinoma).Thelesionsize
was 2.8cm, and spectroscopic voxel (size, 2 × 2 × 2cm 3)
was carefully positioned to maximize the coverage of the hy-
pointense lesion on the centered sagittal image and on the
contrast-enhanced lesion in the subtraction axial image.4 The Scientiﬁc World Journal
Table 1: Summary of tumor size, tCho detection rate, and tCho concentration level in morphological types.
Tumor morphology Mean size (cm)∗∗ No. of true positives No. of false negatives tCho detection rate Mean tCho (mmol/kg)
Mass 2.5 53 25 82% 2.76
Nonmass 4.8 12 9 57% 2.39
Tumor size (cm) was calculated by taking the square root of the product (e.g., the longest dimension × the longest perpendicular dimension of the maximum
intensity projection (MIP) of the MR subtraction images). ∗∗P<0.0002, where the signiﬁcance level was set at P<0.05. There is no signiﬁcant group
diﬀerence in tCho level (P>0.05).
Table 2: Summary of tumor size, tCho detection rate, and tCho concentration level in histopathological types.
Tumor type Mean size (cm) No. of true positives No. of false negatives tCho detection rate∗ Mean tCho (mmol/kg)
IC 2.9 62 26 71% 2.65
IDC 3.2 49 17 74% 2.49
ILC 2.3 5 5 50% 2.70
Mixed 2.4 8 4 67% 3.92
DCIS 2.4 3 8 27% 1.57
Benign 1.6 1 (false+) 12 (true−)0 . 6 6
IC: invasive cancer, IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma, mixed: mixed invasive ductal and lobular carcinoma, and DCIS:d u c t a l
carcinoma in situ. ∗P = 0.025 (IC versus DCIS), where the signiﬁcance level was set at P<0.05.
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Figure 1: The ROC curve generated from the tCho concentration
level measured in the 112 lesions (99 malignant and 13 benign).
With a tCho cut-oﬀ point of >0.0mmol/kg, the overall accuracy
was 69%, with a sensitivity of 66% and a speciﬁcity of 93%.
The elevated tCho peak at 3.22ppm is clearly detected in the
water-fat suppressed spectrum. The Gaussian model ﬁtting
produces a measurement of [tCho] = 8.51 ± 0.98mmol/kg,
theestimatedmodelﬁtisshownabovethefullspectrum,and
the residue is shown underneath. Figure 3 shows MRI and
1H-MRS from a patient with a benign ﬁbrocystic changes.
This patient showed dense glandular tissues on the sagittal-
view precontrast image, and on the axial view subtraction
image a heterogeneous enhancement area was noted in the
posterior right breast. 1H-MRS demonstrated an increased
tCho
H2O
[tCho] = 8.51 ±0.98 mmol/kg
6543210
(ppm)
Tau Cr
Figure2:MRIandMRSmeasurementinapatientwithmixedinva-
sive ductal and lobular carcinoma. The equivalent 1-dimensional
tumor size was 2.8cm, and the spectroscopic voxel (size 2 × 2 ×
2cm 3) was superimposed on the hypointense lesion in the pre-
contrast sagittal image. The elevated tCho peak at 3.2ppm is clearly
visible in the water-fat suppressed spectrum. The Gaussian model
ﬁttingofthetChopeakproducesameasurementof[tCho] =8.51 ±
0.98mmol/kg, the estimated model ﬁt is shown above the full spec-
trum, and the residue is shown underneath. Creatine (Cr) peak at
3.02ppm and taurine (Tau) peak at 3.45ppm are also observed.
tCho peak in the enhanced areas. The Gaussian model ﬁtting
of the tCho peak yields a measurement of [tCho] = 0.66 ±
0.10mmol/kg, and the residue is shown underneath.
Figure4showsthetCholevelsofallindividualpatientsin
each of the four groups. A large variation was observed in all
groups.Nosigniﬁcantgroupdiﬀerenceswereobservedinthe
tCho concentration levels (P>0.05). The mean values were
2.49 for IDC, 2.70 for ILC, 3.92 for mixed, and 1.57mmol/kg
for DCIS, respectively.
Figure5showsthesensitivityofbreast 1H-MRSinmalig-
nant tumor size groups. The sensitivity increased from 46%
(16/35, Group A), to 70% (21/30, Group B), to 82% (28/34,
Group C), in a statistically signiﬁcant manner (P<0.0001,The Scientiﬁc World Journal 5
tCho
H2O
[tCho] = 0.66 ±0.1 mmol/kg
6543210
(ppm)
Figure 3: MRI and MRS measurement in a patient with false-
positive benign lesion. This patient showed dense glandular tissues
on the sagittal precontrast image and mild enhancement on the
enhanced MR image. The spectroscopic voxel size was 2 × 2 ×
2cm 3. The elevated tCho peak at 3.2ppm is clearly visible in the
water-fat suppressed spectrum. The Gaussian model ﬁtting of the
tCho peak yields a measurement of [tCho] = 0.66 ± 0.10mmol/kg,
the estimated model ﬁt is shown above the full spectrum, and the
residue is shown underneath.
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Figure 4: Plot of tCho concentration versus tumor type. The tCho
concentrationlevelwasmeasuredfrom65true-positivelesions,and
the range was from 0.08–9.99 (mean ± SD, 2.7 ± 2.3mmol/kg),
consistent with the previously published value. The mean tCho
levels were IDC = 2.49, ILC = 2.70, mixed = 3.92, and DCIS =
1.57mmol/kg. The mean tCho levels were found to be higher in
invasive cancer compared to noninvasive cancer, possibly associated
with more aggressive behavior or faster cell replication in invasive
cancer.
two-sided exact Kruskal-Wallis test). The overall sensitivity
was 66% (65/99). When a smaller size was chosen (<1.5cm),
the sensitivity was further decreased (29%, 4/14). Figure 6
showsthesensitivityof 1H-MRSinhistopathologicalgroups.
The sensitivity was signiﬁcantly higher in invasive cancer
(71%, 62/88) than in noninvasive cancer, DCIS (27%, 3/11)
(P<0.03). Among invasive cancers, the 1H-MRS sensitivity
P<0.001
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Figure 5: Sensitivity of breast 1H-MRS in diﬀerent tumor size
groups. The sensitivity increased from 46% (Group A, 1.0–1.9cm),
to 70% (Group B, 2.0–2.9cm), and 82% (Group C, 3.0cm and
above), in a statistically signiﬁcant manner (P<0.0001, two-sided
exact Kruskal-Wallis test).
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Figure 6: Sensitivity of breast 1H-MRS in diﬀerent histopathologi-
cal lesion groups. The sensitivity was signiﬁcantly higher in invasive
cancer than in noninvasive cancer, ductal carcinoma in situ (P<
0.03). The sensitivity was higher in IDC compared to ILC, but not
signiﬁcant (P>0.05).
was higher in IDC (74%, 49/66) compared to ILC (50%,
5/10), but not signiﬁcant (P>0.05).
4. Discussion
In vivo 1H-MRS is a noninvasive technique that has great
potential to provide complementary information to improve
breastcancerdiagnosis.Thediagnosticvalueofinvivo breast
MR spectroscopy is typically based on the detection of
elevated level of tCho, which is a marker of active tumor.6 The Scientiﬁc World Journal
Quantitative measurement of tCho may improve the accu-
racy of lesion diagnosis because the sensitivity of 1H-MRS is
variable due to variations in voxel size, adipose tissue con-
tent, and receiver coil eﬃciency. The present study analyzed
the quantitative single-voxel 1H-MRS data using the ROC
analysisandsetthecriteriabasedonthecut-oﬀpointastCho
level >0.0mmol/kg. Using this criterion, the sensitivity and
speciﬁcity were 66% and 92%, respectively. They were in the
similar range as reported in previously published study [14].
The measured tCho concentration levels in this work
were within a range of 0.08–9.99 (mean ± SD, 2.7 ±
2.3mmol/kg) from 66 of 99 patients with malignant breast
tumors using 1.5T, which are consistent with the ﬁndings
of previous published results. Roebuck et al. [8] found tCho
levels ranging 0.4–5.8mmol/L in seven patients with con-
ﬁrmed malignant breast tumors. Bakken et al. [15]r e p o r t e d
2.0mM of choline-containing compounds found in a single
breast cancer patient. Baek et al. [17] reported that the
tCho levels had a range of 0.32–10.47mmol/kg from 32 pa-
tient with malignant breast tumors at 1.5T. Bolan et
al. [14] reported a range of tCho measurements of 0.40–
10.0mmol/kgin71malignantbreasttissuespectraat4T.The
largerangeintChoconcentrationlevelsformalignantlesions
was observed. This result may reﬂect the heterogeneous
nature of breast lesions. Gribbestad et al. [26]r e p o r t e d
that phosphatidylcholine, a precursor of choline-derived
phospholipids, also showed a large variation even among the
same tumor types. Ting et al. [27] reported that the increase
of choline has often been reported in breast cancer and is
regarded as a marker for elevated proliferation rates. Singer
et al. [28] reported that the metastatic breast cancer cell line
21MT-2 had a signiﬁcantly higher concentration of choline
than did the primary breast cancer cell lines 21PT and 21NT.
In this study, 1H-MRS detected one of 13 patients
with benign lesion as a false-positive case, with tCho
level of 0.66mmol/kg (Figure 3). In some of the previous
studies, tCho peaks were detected in benign lesions at
1.5T: Roebuck et al. [8] (one case), Kvistad et al. [9] (two
cases), Jagannathan et al. [10]( e i g h tc a s e s ) ,Y e u n ge ta l .[ 12]
(one case), and Cecil et al. [13] (two cases). Stanwell and
Mountford [29] also reported detecting tCho peak in false-
positive volunteers or lactating mothers at 1.5T. Thus, these
false-positive cases probably represent the actual limits of the
speciﬁcity of breast 1H-MRS in diagnosis of breast cancer.
Recently, Haddadin et al. [30] reported that tCho concentra-
tion level was higher in cancers than in benign lesions or
normal breast tissues at 4T high ﬁeld. Comparing only
the benign and malignant measurements, an ROC analysis
led to a cutoﬀ of 1.45mmol/kg, giving 73% sensitivity
and 77% speciﬁcity for distinguishing benign from malig-
nant lesions. For in vivo 1H-MRS using 1.5T, however, fur-
ther investigation in a large population (e.g., benign le-
sions) is needed to determine a threshold tCho value for dif-
ferentiating between malignant and benign lesions.
In vivo 1H-MRS studies have demonstrated that elevated
tCho peak at 3.2ppm is observed in neoplastic tissues [8, 9,
12, 13]. However, the precise mechanism for elevated tCho is
not completely understood and still remains unclear. High-
resolution 1H-NMR spectra acquired from biopsy tissues
have shown that a tCho resonance peak actually is comprised
of multiple signals, such as phosphocholine, glycerophos-
phocholine, and free choline [31]. These three signals cannot
be resolved in vivo at 1.5T, at which only a single resonance
peak, representing the aggregate of all choline-containing
compounds, is observed. Among these signals, the primary
component contributing to the tCho peak is phospho-
choline, a known precursor of cell membranes synthesis [26,
27,32].Theincreasedcholinekinase(ChoK)anditsproduct,
phosphocholine, have been implicated in human carcino-
genesis [33]. Thus, the elevated tCho level in breast cancer
may be associated with increased membrane synthesis by
replicatingcells.However,benigntissuessuchasproliferative
ﬁbroadenomas may also show a positive tCho signal [12].
In this study, tCho detection rate was higher in invasive
cancer (e.g., IDC, ILC, and mixed) compared to DCIS,
possibly associated with more aggressive behavior or faster
cellreplication(Figure4).Thisﬁndingisconsistentwithpre-
viously reported results, showing that, on in vivo 1H-MRS,
IDC was consistently positive for tCho detection, where-
as DCIS was likely negative [34]. 3 (27%) of 11 patients
with DCIS in our study were positive for tCho detection,
but the remaining 8 (73%) patients had false-negative cases.
The tCho detection rate was also higher in IDC (75%, 49/65)
compared to ILC (55%, 6/11), which was possibly related
to the inﬁltrating phenotype of ILC, thus, more susceptible
to the fat contamination problem (Table 2). However, there
was no signiﬁcant diﬀerence in the tCho detection rate and
concentration level between invasive cancers, which is con-
sistent with the ﬁndings of previous study [35]. The lipid
contamination in 1H-MRS voxel may attribute to low sen-
sitivity [17]. The adipose tissue limits the ability to optimize
the ﬁeld homogeneity inside the selected 1H-MRS volume,
which in turn leads to broad resonance peaks and reduced
SNR. Recently, Thakur et al. [35] reported that water-to-fat
(W/F) ratio measure from in vivo 1H-MRS may be useful
to diﬀerentiate IDC from ILC tumors because the ratio was
signiﬁcantly higher in the IDC lesions compared to the ILC
lesions(P<0.001).IDCtumorsformfocalmassesandoblit-
erate background tissue as it grows, while ILC tumors are
connected as a single strand, and these invade tissue without
formation of focal mass, preserving background fat [36, 37].
Of the 99 malignant lesions, there were 34 false-negative
cases, which resulted in 66% sensitivity (Table 2). This might
be due to partial volume eﬀects from intermixed tumor and
normal tissues in a 1H-MRS voxel. Due to this problem, in
vivo single-voxel 1H-MRS will have a very limited role for
characterizingsmalllesions.Whenthedataweredividedinto
threesizegroups(e.g.,<2.0,2.0–2.9, ≥3.0cm),thesensitivity
of the 1H-MRS in these size-dependent subgroups increased
from 46% to 70% and to 82%, in a statistically signiﬁcant
manner (Figure 5). More than half of lesions smaller than
2.0cm (54%) had false-negative diagnosis, because of the
lack of a detectable tCho signal. When a smaller size was
chosen(<1.5cm),thesensitivitywasfurtherdecreased(29%,
4/14). Therefore, further improvement in the signal-to-noise
ratio may enhance the detection of tCho and improve the
diagnostic sensitivity. One approach is to use the scanner
at a higher magnetic ﬁeld, but it may suﬀer from a worseThe Scientiﬁc World Journal 7
ﬁeldinhomogeneityproblem.Nolargecohortstudyhasbeen
reported from 3T yet.
In conclusion, in this study we reported diagnostic
value of quantitative in vivo 1H-MRS spectroscopy at 1.5T
in diﬀerent histopathological types. On the basis of that
threshold (e.g., >0.66mmol/kg), 1H-MRS alone presented
58% sensitivity and 100% speciﬁcity for diagnosis. The tCho
levels were found to be higher in invasive cancer compared
to DCIS or benign lesions, possibly associated with more
aggressive behavior or faster cell replication in invasive can-
cer. Therefore, quantitative 1H-MRS may provide useful in-
formation for characterizing tumor types of breast cancer.
However, in vivo 1H-MRS at 1.5T has a limited role for char-
acterizing small lesions.
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